Abstract
Objective: PARP inhibitors offer substantial clinical benefit to ovarian cancer (OC) patients in multiple treatment settings. However, their price is considerable, and patients may be at risk for financial toxicity. For other disease sites, a $10 increase in out-of-pocket costs for oral anticancer treatment is associated with a 10%–20% increased likelihood of treatment discontinuation/delay. The amount of cost-sharing OC patients may experience while receiving PARP treatment is not well understood.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
